LOQUS23 THERAPEUTICS
London
About LOQUS23 THERAPEUTICS
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease and other triplet repeat diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $61.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Oct 2024)
- Website: loqus23.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/loqus23-therapeutics-92865 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.